Hudson Bay Capital Management LP Sells 235,000 Shares of Intellia Therapeutics, Inc. $NTLA

Hudson Bay Capital Management LP lowered its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 50.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 230,000 shares of the company’s stock after selling 235,000 shares during the quarter. Hudson Bay Capital Management LP owned about 0.20% of Intellia Therapeutics worth $3,972,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CWM LLC raised its holdings in Intellia Therapeutics by 4.7% in the third quarter. CWM LLC now owns 19,187 shares of the company’s stock worth $331,000 after purchasing an additional 856 shares in the last quarter. Federated Hermes Inc. lifted its position in shares of Intellia Therapeutics by 39.7% during the third quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock valued at $56,000 after buying an additional 927 shares during the last quarter. Cyndeo Wealth Partners LLC boosted its holdings in shares of Intellia Therapeutics by 9.3% in the 3rd quarter. Cyndeo Wealth Partners LLC now owns 11,710 shares of the company’s stock valued at $202,000 after buying an additional 995 shares in the last quarter. Interchange Capital Partners LLC boosted its holdings in shares of Intellia Therapeutics by 9.7% in the 3rd quarter. Interchange Capital Partners LLC now owns 11,695 shares of the company’s stock valued at $202,000 after buying an additional 1,030 shares in the last quarter. Finally, Benjamin Edwards Inc. grew its position in shares of Intellia Therapeutics by 1.8% in the 2nd quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock worth $591,000 after buying an additional 1,126 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Insider Transactions at Intellia Therapeutics

In other news, EVP James Basta sold 10,397 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $95,756.37. Following the sale, the executive vice president directly owned 101,528 shares of the company’s stock, valued at $935,072.88. The trade was a 9.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John M. Leonard sold 34,146 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $314,484.66. Following the sale, the chief executive officer directly owned 1,013,339 shares in the company, valued at $9,332,852.19. This trade represents a 3.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 53,051 shares of company stock worth $488,600. Company insiders own 3.10% of the company’s stock.

Wall Street Analysts Forecast Growth

NTLA has been the subject of several recent analyst reports. Leerink Partners boosted their price objective on shares of Intellia Therapeutics from $27.00 to $29.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Thursday, January 22nd. Wells Fargo & Company lifted their price target on shares of Intellia Therapeutics from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 3rd. JonesTrading raised Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a research report on Wednesday, March 4th. Finally, Royal Bank Of Canada increased their price objective on Intellia Therapeutics from $9.00 to $15.00 and gave the company a “sector perform” rating in a report on Tuesday, March 3rd. Ten equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Intellia Therapeutics has an average rating of “Hold” and a consensus price target of $19.59.

Intellia Therapeutics Stock Down 2.4%

NTLA opened at $12.84 on Friday. The company has a market cap of $1.52 billion, a P/E ratio of -3.35 and a beta of 2.10. The firm’s 50-day moving average price is $13.06 and its 200-day moving average price is $13.29. Intellia Therapeutics, Inc. has a 52-week low of $5.90 and a 52-week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, February 26th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.16. The company had revenue of $23.02 million during the quarter, compared to analysts’ expectations of $12.17 million. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. Intellia Therapeutics’s revenue for the quarter was up 78.4% on a year-over-year basis. During the same period last year, the business earned ($1.27) EPS. On average, research analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.